EBS · XBRL financial data

Emergent BioSolutions financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (EBS's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	277*	300	255	294	195*	—	—	—	year only	—	—	—
Revenue from contracts with customers	year only	300	255	294	195*	222	141	231	149*	156	234	110
Cost of goods and services sold	185*	145	296	123	118*	89	67	86	85*	72	97	81
Gross profit	—	148	(48)	161	—	—	—	—	—	—	—	—
Research and development	29*	15	33	14	9*	15	13	14	12*	11	9	9
Selling, general and administrative	90*	85	86	77	61*	52	44	39	51*	47	45	47
Operating income (loss)	(44)*	40	(204)	65	(10)*	50	2	77	(28)*	11	(125)	(37)
Interest expense	22*	24	24	8	15*	15	15	15	15*	11	10	10
Other income (expense)	11*	(3)	(3)	22	(3)*	70	(4)	(4)	(8)*	14	0	4
Income tax expense (benefit)	(5)*	3	13	28	4*	25	(5)	6	4*	7	14	(4)
Net income (loss)	(50)*	9	(283)	115	(31)*	68	(12)	51	(55)*	7	(180)	(33)
Earnings per share, basic USD per share	(0.95)*	0.17	(5.38)	2.16	(0.58)*	1.25	(0.22)	0.96	(1.05)*	0.13	(3.49)	(0.64)
Earnings per share, diluted USD per share	(0.95)*	0.17	(5.38)	2.06	(0.61)*	1.19	(0.22)	0.91	(0.93)*	0.07	(3.49)	(0.64)
Weighted average shares, basic millions of shares	52*	52	53	53	54*	54	54	53	52*	52	52	51
Weighted average shares, diluted millions of shares	52*	52	53	56	52*	57	54	57	59*	57	52	51

Fiscal quarters (EBS's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	112	79	70	150	100	149	267	246	205	160	140	176
Accounts receivable	191	234	196	121	155	204	80	150	84	122	190	78
Inventory	329	333	318	323	312	314	339	356	343	328	304	281
Prepaid and other current assets	48	37	36	61	27	30	24	26	26	27	25	23
Total current assets	680	682	655	661	599	707	720	787	663	638	666	558
Property and equipment, net	383	379	306	278	271	221	216	210	205	199	178	175
Right-of-use asset	16	15	14	12	12	7	8	7	11	10	6	5
Goodwill	0	0	0	0	0	—	—	—	0	—	—	—
Total assets	1,823	1,804	1,514	1,478	1,390	1,426	1,417	1,461	1,319	1,320	1,117	995
Accounts payable	112	100	96	82	61	58	64	57	56	40	50	52
Accrued liabilities	19	14	17	16	18	13	14	14	12	9	17	8
Current portion of long-term debt	414	459	415	1	0	—	—	—	—	—	—	—
Total current liabilities	651	630	620	230	162	112	127	137	132	149	123	122
Long-term debt	447	447	447	662	664	666	668	663	572	574	582	508
Lease liability, non-current	14	13	12	11	10	5	7	6	9	9	5	5
Total liabilities	1,174	1,140	1,127	969	907	873	881	879	796	797	775	682
Accumulated deficit	(22)	(13)	(296)	(181)	(212)	(144)	(156)	(105)	(160)	(153)	(333)	(366)
Total stockholders' equity	649	664	386	508	483	553	536	583	523	523	341	313
Total liabilities and equity	1,823	1,804	1,514	1,478	1,390	1,426	1,417	1,461	1,319	1,320	1,117	995
Common shares outstanding (cover page) millions of shares	52	52	53	54	54	54	53	53	52	52	51	51

Fiscal quarters (EBS's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(50)*	9	(283)	115	(31)*	68	(12)	51	(55)*	7	(180)	(33)
Stock-based compensation	4*	6	6*	2*	4*	2	5*	5*	5*	2	7*	4*
Depreciation and amortization	30*	28	29*	26*	26*	25	24*	23*	24*	24	24*	17*
Net cash from operating activities	32*	(63)	48*	154*	(80)*	(11)	106*	(2)*	78*	(34)	56*	100*
Purchases of property and equipment	11*	11	5*	6*	2*	4	3*	3*	4*	2	2*	3*
Net cash from investing activities	(11)*	(11)	(5)*	112*	29*	60	17*	(3)*	(4)*	(2)	(52)*	5*
Proceeds from issuing common stock	0*	—	—	0*	0*	0	—	—	(1)*	0	—	—
Share repurchases	0*	—	—	0*	0*	0	7*	9*	9*	9	9*	0*
Net cash from financing activities	5*	41	(51)*	(180)*	1*	(0)	(6)*	(16)*	(114)*	(11)	(24)*	(69)*
Net change in cash	24*	(33)	(8)*	85*	(51)*	47	118*	(22)*	(40)*	(48)	(21)*	36*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Emergent BioSolutions	176	110	100*	51.4M	—	Q3 FY26 10-QSep 30, 2026
Northwest Biotherapeutics	0.6	0.8	(7.2)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Amarin	157	40	9.2*	not reported	—	Q3 FY26 10-QSep 30, 2026
Rigel Pharmaceuticals	61	79	31*	18.7M	—	Q2 FY26 10-QJun 30, 2026
Usana Health Sciences	169	223	23*	18.5M	—	Q2 FY26 10-QJul 4, 2026
Altimmune	63	not reported	(24)*	194.5M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Prothena Corp Public	288	1	(25)*	51.3M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Aura Biosciences	68	not reported	(33)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Nektar Therapeutics	39	10	(76)*	34.1M	9.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.